RNS Number:3593I
Medical Marketing Int'l Group PLC
06 March 2003


For Immediate Release                                           6th March 2003



                                      MMI

                               LAUNCHES TEK-CHECK



                      Technical & Commercial Due Diligence

                          For The Lifesciences Sector



Medical Marketing International Group plc (MMI), the Cambridge UK based
technology management company (LSE: MMG) is delighted to announce the launch of
Tek-check*, a technical and commercial due diligence service specially designed
by MMI for the lifesciences sector.



MMI can already confirm that Tek-check will be available to Relationship
Managers of NatWest Bank plc and The Royal Bank of Scotland plc as a due
diligence service for their life sciences based cases and similarly preferred
provider to The Bioscience VCT. As such, Tech-check will be a valued part of the
decision making process for all of these organisations.



Tek-check will provide MMI with a further income stream and compliments the
outsourcing services currently available through MMI's consultancy division
which include fully-integrated technology sourcing, selection, mentoring and
incubation programmes.  Importantly it demonstrates MMI's strategy of providing
a more balanced revenue model through focussing on short to medium term revenues
with its consultancy services together with longer term upside through its
technology pipeline.



In the last decade the bioscience and nanotechnology industries have seen rapid
technological advances, often driven by small start-up companies that focus on
innovative, early-stage technologies.  The rewards of investing in these
companies can be high, but then again so are the risks.  Consequently, a careful
and skilful due diligence on the investment proposition offered by early-stage
technology companies is a vital tool for potential investors in their
decision-making process.  Due diligence of this nature is no longer the remit of
the single expert, but requires a multi-disciplinary team that understands the
complexities of taking early-stage technologies from inception through to the
market place, especially in the increasingly regulated area of biotechnology.



Tek-check provides potential investors with technical and commercial due
diligence that is:



Independent.  A third party evaluation by a team of experts gives a level of
confidence with a technology investment.



Comprehensive.  Answers provided to the key questions:



What are the risks and benefits of the technology?

Is the technology really innovative?

Is there adequate intellectual property protection for the technology?  Is it
defensible?

Is there a commercial opportunity?

What are the development challenges?

Does the business strategy make sense?

Can the management deliver?



Who will benefit from Tek-check?



MMI will be primarily targeting investment organisations including venture
capitalists, banks, institutional investors, private equity investors, and
business angel networks.

Similarly, companies or individuals seeking to value a technology, product or
company as part of an investment or business decision - spin-outs, start-ups,
licensing, joint ventures or strategic alliances - will also gain invaluable
third party advice from Tek-check.



Commenting on the Tek-check launch, David Best, Chairman of MMI said: "I have
enormous confidence that Tek-check will provide an invaluable service to the
industry, offering detailed due-diligence and bringing to the fore the best
technologies within our industry.  Equally, we are delighted to already have
attracted three of the leading players within the sector, and believe that
Tek-check will become an integral part of the due-diligence process within the
industry.



                                    - Ends -



For further information, please contact:


David Best - Executive Chairman
MMI Group                                             Tel: +44 (0)1223 477677
www.mmigroup.plc.com

Lisa Baderoon
Buchanan Communications                               Tel: +44 (0)20 7466 5000

Or visit
w.tek-check.com





* Trademark applied for



NOTES TO EDITORS



Royal Bank of Scotland plc & NatWest Bank plc



The Royal Bank of Scotland group (incorporating NatWest) is the UK's second
largest Bank and is a market leader in the provision of Banking services to
technology based businesses.  It has a network of specifically trained
Technology Managers supported by a dedicated central Group.



For more information, please contact:

Stuart Ager, Head of Technology Sector Group

Tel No:  020 7672 1844

e-mail - stuart.ager@rbs.co.uk



The Bioscience VCT



The Bioscience VCT (BSVCT) was launched in October 2001 and is Britain's first
venture capital trust focused on the biomedical sector.  The Fund was
established to enable investors to have a stake in a portfolio of biomedical
investments whilst enjoying the tax advantages of a VCT.  In its first year the
BSVCT raised approximately #7 million and is currently open for further
investments.  MMI Group is technology manager to BSVCT and Octopus Asset
Management is the Fund Manager.



For more information, please contact:

Chris Hulatt, Octopus Asset Management

Tel No:  0207 255 7960

e-mail -  chulatt@octopusam.com.



or



John Hustler, MMI Group

Tel No:  01223 477677

e-mail - john.hustler@mmigroup.co.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

PRLILFFTVAIEIIV